Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINGRIX Vaccine in CLL Patients
NCT03702231Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (3 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Participants With Varicella Zoster Virus (VZV) Seroprotective Titer at 6 months. Started Dec 2018; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT03702231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702231.